Ginkgo Bioworks Holdings (DNA) Cash from Operations (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Cash from Operations of 46433000.0 for Q1 2026, up 2.61% on a QoQ basis from 47678000.0 in Q4 2025, and down 8.62% year-over-year from 50811834.56 in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Cash from Operations (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Cash from Operations history runs 7 years deep, the most recent figure standing at 46433000.0 for Q1 2026.
- Quarterly Cash from Operations fell 8.62% year-over-year to 46433000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 174743000.0 (up 36.01% YoY) and the FY2025 annual result came in at 171059000.0, up 46.47% from the prior year.
- Cash from Operations was 46433000.0 for Q1 2026 at Ginkgo Bioworks Holdings, up from 47678000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 19898000.0 in Q1 2022 and bottomed at 104531000.0 in Q4 2022.
- A 5-year average of 63810294.12 and a median of 57831000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 441.76% — and 2025, when it surged 69.46%.
- Ginkgo Bioworks Holdings' Cash from Operations stood at 104531000.0 in 2022, then surged by 44.68% to 57831000.0 in 2023, then climbed by 26.62% to 42435000.0 in 2024, then declined by 12.36% to 47678000.0 in 2025, then gained by 2.61% to 46433000.0 in 2026.
- Business Quant data shows DNA's Cash from Operations at 46433000.0 in Q1 2026, 47678000.0 in Q4 2025, and 31606000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -46.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.43 Mn |
| Mar 31, 2026 | -46.43 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Sep 30, 2025 | -31.61 Mn |
| Sep 30, 2025 | -31.61 Mn |
| Jun 30, 2025 | -49.03 Mn |
| Jun 30, 2025 | -49.03 Mn |
| Mar 31, 2025 | -42.75 Mn |
| Mar 31, 2025 | -42.75 Mn |
| Dec 31, 2024 | -42.44 Mn |
| Dec 31, 2024 | -42.44 Mn |
| Sep 30, 2024 | -103.50 Mn |
| Sep 30, 2024 | -103.50 Mn |
| Jun 30, 2024 | -84.39 Mn |
| Jun 30, 2024 | -84.39 Mn |
| Mar 31, 2024 | -89.26 Mn |
| Mar 31, 2024 | -89.26 Mn |
| Dec 31, 2023 | -57.83 Mn |
| Dec 31, 2023 | -57.83 Mn |